ATAI Life Sciences
ATAI Life Sciences AG is a biotechnology company based in Munich, Germany, with additional offices in Berlin and London. Founded in 2018, the company focuses on developing innovative therapies for mental health disorders, including depression, anxiety, and substance use disorders. ATAI utilizes psychedelic compounds and other therapeutic methods to address these conditions, collaborating with various partners and research institutions to enhance its drug development pipeline. Its clinical-stage product portfolio features therapies such as COMP360 (Psilocybin therapy), PCN-101 (R-ketamine), and others derived from compounds like MDMA and ibogaine. By working with experts in the field, ATAI aims to ensure the efficacy and safety of its treatments. The company has garnered recognition for its contributions to mental health research and has secured partnerships and funding to further its initiatives in transforming mental health care.
Past deals in Montreal
Intelgenx Technologies
Acquisition in 2024
IntelGenx Technologies Corp., established in 2003 and headquartered in Montreal, Canada, specializes in the development and manufacturing of innovative pharmaceutical oral films using its proprietary VersaFilm™ technology platform. The company focuses on creating novel oral thin film products for the pharmaceutical market, offering a range of services including R&D, clinical monitoring, regulatory support, and manufacturing. IntelGenx's portfolio comprises products like RIZAPORT for migraine treatment, and various others under development for conditions such as depression, erectile dysfunction, and Alzheimer's disease. The company collaborates with pharmaceutical partners through co-development, licensing, and supply agreements, generating a significant portion of its revenue from Europe.
Intelgenx Technologies
Post in 2023
IntelGenx Technologies Corp., established in 2003 and headquartered in Montreal, Canada, specializes in the development and manufacturing of innovative pharmaceutical oral films using its proprietary VersaFilm™ technology platform. The company focuses on creating novel oral thin film products for the pharmaceutical market, offering a range of services including R&D, clinical monitoring, regulatory support, and manufacturing. IntelGenx's portfolio comprises products like RIZAPORT for migraine treatment, and various others under development for conditions such as depression, erectile dysfunction, and Alzheimer's disease. The company collaborates with pharmaceutical partners through co-development, licensing, and supply agreements, generating a significant portion of its revenue from Europe.
Intelgenx Technologies
Post in 2023
IntelGenx Technologies Corp., established in 2003 and headquartered in Montreal, Canada, specializes in the development and manufacturing of innovative pharmaceutical oral films using its proprietary VersaFilm™ technology platform. The company focuses on creating novel oral thin film products for the pharmaceutical market, offering a range of services including R&D, clinical monitoring, regulatory support, and manufacturing. IntelGenx's portfolio comprises products like RIZAPORT for migraine treatment, and various others under development for conditions such as depression, erectile dysfunction, and Alzheimer's disease. The company collaborates with pharmaceutical partners through co-development, licensing, and supply agreements, generating a significant portion of its revenue from Europe.
Intelgenx Technologies
Post in 2022
IntelGenx Technologies Corp., established in 2003 and headquartered in Montreal, Canada, specializes in the development and manufacturing of innovative pharmaceutical oral films using its proprietary VersaFilm™ technology platform. The company focuses on creating novel oral thin film products for the pharmaceutical market, offering a range of services including R&D, clinical monitoring, regulatory support, and manufacturing. IntelGenx's portfolio comprises products like RIZAPORT for migraine treatment, and various others under development for conditions such as depression, erectile dysfunction, and Alzheimer's disease. The company collaborates with pharmaceutical partners through co-development, licensing, and supply agreements, generating a significant portion of its revenue from Europe.
Intelgenx Technologies
Post in 2021
IntelGenx Technologies Corp., established in 2003 and headquartered in Montreal, Canada, specializes in the development and manufacturing of innovative pharmaceutical oral films using its proprietary VersaFilm™ technology platform. The company focuses on creating novel oral thin film products for the pharmaceutical market, offering a range of services including R&D, clinical monitoring, regulatory support, and manufacturing. IntelGenx's portfolio comprises products like RIZAPORT for migraine treatment, and various others under development for conditions such as depression, erectile dysfunction, and Alzheimer's disease. The company collaborates with pharmaceutical partners through co-development, licensing, and supply agreements, generating a significant portion of its revenue from Europe.
Intelgenx Technologies
Post in 2021
IntelGenx Technologies Corp., established in 2003 and headquartered in Montreal, Canada, specializes in the development and manufacturing of innovative pharmaceutical oral films using its proprietary VersaFilm™ technology platform. The company focuses on creating novel oral thin film products for the pharmaceutical market, offering a range of services including R&D, clinical monitoring, regulatory support, and manufacturing. IntelGenx's portfolio comprises products like RIZAPORT for migraine treatment, and various others under development for conditions such as depression, erectile dysfunction, and Alzheimer's disease. The company collaborates with pharmaceutical partners through co-development, licensing, and supply agreements, generating a significant portion of its revenue from Europe.
Spot something off? Help us improve by flagging any incorrect or outdated information. Just email us at support@teaserclub.com. Your feedback is most welcome.